Cargando…

Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor

BACKGROUND: 2‐deoxy‐2‐[fluorine‐18] fluoro‐d‐glucose ((18)F‐FDG) positron emission tomography ((18)F‐FDG‐PET) is a convenient modality to assess the metabolic activity within tumor cells. However, there is no consensus regarding the relationship between (18)F‐FDG uptake and the immune environment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hisao, Kaira, Kyoichi, Hashimoto, Kosuke, Nitanda, Hiroyuki, Taguchi, Ryo, Yanagihara, Akitoshi, Umesaki, Tetsuya, Yamaguchi, Ou, Mouri, Atsuto, Kawasaki, Tomonori, Yasuda, Masanori, Kobayashi, Kunihiko, Sakaguchi, Hirozo, Kuji, Ichiei, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446555/
https://www.ncbi.nlm.nih.gov/pubmed/34363337
http://dx.doi.org/10.1002/cam4.4176
_version_ 1784568905714368512
author Imai, Hisao
Kaira, Kyoichi
Hashimoto, Kosuke
Nitanda, Hiroyuki
Taguchi, Ryo
Yanagihara, Akitoshi
Umesaki, Tetsuya
Yamaguchi, Ou
Mouri, Atsuto
Kawasaki, Tomonori
Yasuda, Masanori
Kobayashi, Kunihiko
Sakaguchi, Hirozo
Kuji, Ichiei
Kagamu, Hiroshi
author_facet Imai, Hisao
Kaira, Kyoichi
Hashimoto, Kosuke
Nitanda, Hiroyuki
Taguchi, Ryo
Yanagihara, Akitoshi
Umesaki, Tetsuya
Yamaguchi, Ou
Mouri, Atsuto
Kawasaki, Tomonori
Yasuda, Masanori
Kobayashi, Kunihiko
Sakaguchi, Hirozo
Kuji, Ichiei
Kagamu, Hiroshi
author_sort Imai, Hisao
collection PubMed
description BACKGROUND: 2‐deoxy‐2‐[fluorine‐18] fluoro‐d‐glucose ((18)F‐FDG) positron emission tomography ((18)F‐FDG‐PET) is a convenient modality to assess the metabolic activity within tumor cells. However, there is no consensus regarding the relationship between (18)F‐FDG uptake and the immune environment in thymic epithelial tumors (TETs). We conducted a clinicopathological study to elucidate the relationship between (18)F‐FDG uptake and programmed death ligands 1 and 2 (PD‐L1/PD‐L2) expression in patients with TETs. Methods: A total of 108 patients with histologically confirmed TETs classified as thymomas or thymic carcinomas who underwent surgical resection or biopsy or needle biopsy and (18)F‐FDG PET before any treatment between August 2007 and March 2020 were enrolled in this study. Tumor specimens underwent immunohistochemical staining for PD‐L1, PD‐L2, GLUT1, HIF‐1α, VEGFR2, VEGF‐C, and β2 adrenergic receptor. Results: High uptakes of SUV(max), SUV(mean), MTV, and TLG were identified in 28 (25.9%), 61 (56.5%), 55 (50.9%), and 55 (50.9%) of 108 patients, respectively. High uptake of SUV(max) significantly correlated with PS (performance status) of 1–2, thymic carcinoma, and advanced stage, and SUV(max) on (18)F‐FDG uptake displayed a close association with PD‐L1 and PD‐L2 expressions, but not with MTV and TLG. Our analysis revealed that SUV(max) was identified as being significant relationship for positive PD‐L1/PD‐L2 expression. GLUT1, HIF‐1α, and VEGFR2 were significantly associated with the expression of PD‐L1/PD‐L2 from the biological viewpoint. CONCLUSION: (18)F‐FDG accumulation was closely associated with the expression of PD‐L1/PD‐L2, which, in turn, was correlated with glucose metabolism and hypoxia. PD‐L1/PD‐L2 could affect the glucose metabolism and hypoxia in thymic tumor cells.
format Online
Article
Text
id pubmed-8446555
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84465552021-09-22 Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor Imai, Hisao Kaira, Kyoichi Hashimoto, Kosuke Nitanda, Hiroyuki Taguchi, Ryo Yanagihara, Akitoshi Umesaki, Tetsuya Yamaguchi, Ou Mouri, Atsuto Kawasaki, Tomonori Yasuda, Masanori Kobayashi, Kunihiko Sakaguchi, Hirozo Kuji, Ichiei Kagamu, Hiroshi Cancer Med Clinical Cancer Research BACKGROUND: 2‐deoxy‐2‐[fluorine‐18] fluoro‐d‐glucose ((18)F‐FDG) positron emission tomography ((18)F‐FDG‐PET) is a convenient modality to assess the metabolic activity within tumor cells. However, there is no consensus regarding the relationship between (18)F‐FDG uptake and the immune environment in thymic epithelial tumors (TETs). We conducted a clinicopathological study to elucidate the relationship between (18)F‐FDG uptake and programmed death ligands 1 and 2 (PD‐L1/PD‐L2) expression in patients with TETs. Methods: A total of 108 patients with histologically confirmed TETs classified as thymomas or thymic carcinomas who underwent surgical resection or biopsy or needle biopsy and (18)F‐FDG PET before any treatment between August 2007 and March 2020 were enrolled in this study. Tumor specimens underwent immunohistochemical staining for PD‐L1, PD‐L2, GLUT1, HIF‐1α, VEGFR2, VEGF‐C, and β2 adrenergic receptor. Results: High uptakes of SUV(max), SUV(mean), MTV, and TLG were identified in 28 (25.9%), 61 (56.5%), 55 (50.9%), and 55 (50.9%) of 108 patients, respectively. High uptake of SUV(max) significantly correlated with PS (performance status) of 1–2, thymic carcinoma, and advanced stage, and SUV(max) on (18)F‐FDG uptake displayed a close association with PD‐L1 and PD‐L2 expressions, but not with MTV and TLG. Our analysis revealed that SUV(max) was identified as being significant relationship for positive PD‐L1/PD‐L2 expression. GLUT1, HIF‐1α, and VEGFR2 were significantly associated with the expression of PD‐L1/PD‐L2 from the biological viewpoint. CONCLUSION: (18)F‐FDG accumulation was closely associated with the expression of PD‐L1/PD‐L2, which, in turn, was correlated with glucose metabolism and hypoxia. PD‐L1/PD‐L2 could affect the glucose metabolism and hypoxia in thymic tumor cells. John Wiley and Sons Inc. 2021-08-07 /pmc/articles/PMC8446555/ /pubmed/34363337 http://dx.doi.org/10.1002/cam4.4176 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Imai, Hisao
Kaira, Kyoichi
Hashimoto, Kosuke
Nitanda, Hiroyuki
Taguchi, Ryo
Yanagihara, Akitoshi
Umesaki, Tetsuya
Yamaguchi, Ou
Mouri, Atsuto
Kawasaki, Tomonori
Yasuda, Masanori
Kobayashi, Kunihiko
Sakaguchi, Hirozo
Kuji, Ichiei
Kagamu, Hiroshi
Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title_full Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title_fullStr Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title_full_unstemmed Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title_short Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
title_sort tumor immunity is related to (18)f‐fdg uptake in thymic epithelial tumor
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446555/
https://www.ncbi.nlm.nih.gov/pubmed/34363337
http://dx.doi.org/10.1002/cam4.4176
work_keys_str_mv AT imaihisao tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT kairakyoichi tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT hashimotokosuke tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT nitandahiroyuki tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT taguchiryo tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT yanagiharaakitoshi tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT umesakitetsuya tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT yamaguchiou tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT mouriatsuto tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT kawasakitomonori tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT yasudamasanori tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT kobayashikunihiko tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT sakaguchihirozo tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT kujiichiei tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor
AT kagamuhiroshi tumorimmunityisrelatedto18ffdguptakeinthymicepithelialtumor